View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Arcadis: Further in German rail. CVC Capital Partners: They beat, they score. D'Ieteren: US Belron peer Boyd 4Q24 a bit ahead, weak 2025 early outlook. Fastned: Preview FY24. IBA: 2H24 better REBIT, net cash but outlook on the low side. Proximus: Interim leadership announced. UCB: Peer Immunovant reports mixed results in gMG Zabka: Peer Jeronimo Martins FY24 results

Jacob Mekhael
  • Jacob Mekhael

UCB FIRST LOOK: New data on pyrimidine nucleoside therapy in TK2d at M...

UCB presented results from studies involving doxecitine (dC) and doxribtimine (dT) (pyrimidine nucleoside therapy) in people living with thymidine kinase 2 deficiency (TK2d), at the MDA Clinical and Scientific Conference, being held 16-19 March in Dallas. The improvements in survival and functional outcomes highlight the potential of doxecitine and doxribtimine in treating TK2d, which is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64/1m peopl...

Guy Sips ... (+3)
  • Guy Sips
  • Jacob Mekhael
  • Sharad Kumar S.P
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Avantium: The final reckoning; Exor: Increasing stake in Philips to 18.7%; IBA: 2H24 preview; Sif Group: Lowers FY25 outlook; UCB: Positive data in TK2d presented at MDA 2025; Vonovia: Positive valuation in 2H24 and good guidance - focus on market dynamics going forwards

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

B&S Group: FY24 results and FY25 outlook in line. UCB: Peer Incyte fails to impress in Hidradenitis Suppurativa

Thomas Vranken
  • Thomas Vranken

UCB J&J and Amgen data drops at AAD 2025

At the American Academy of Dermatology (AAD) 2025 conference, UCB presented strong 5-year follow-up data for Bimzelx in plaque psoriasis and 2-year follow-up in hidradenitis suppurativa. Meanwhile, Johnson & Johnson also announced Phase 3 data for its oral drug icotrokinra in psoriasis, showing promising results and planning further trials. In addition, Amgen reported positive Phase 3 results for rocatinlimab in atopic dermatitis. These developments highlight significant advancements in dermatol...

Guy Sips ... (+4)
  • Guy Sips
  • Michiel Declercq
  • Thomas Vranken
  • Wim Hoste
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
Thomas Vranken
  • Thomas Vranken

UCB FIRST LOOK: 5Y PsO and 2Y HS data further cement Bimzelx' leadersh...

Additional data presented at AAD 2025 further cement Bimzelx' leadership in the IL-17 space for PsO and HS. In PsO, efficacy was well maintained from previous 4-year data into the 5-year follow-up with 67.7% PASI100 and 84.9% PASI90. In HS, additional 2-year data saw 55.7% pts with draining tunnels at baseline, a particularly painful manifestation, reaching clearance after two years. We reiterate our confidence in Bimzelx as an rising leader in the dermatology/rheumatology space, and confirm our...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart

UCB/Strengthening its Immunology portfolio/BUY

We reiterate our BUY rating on UCB and increase our target price from €212 to €220 on the back of a slight increase in Bimzelx's long-term peak sales and Evenity, which is now profitable in Europe. We continue to view UCB's risk/reward balance as favourable, with the group pipeline accounting for only 6% of Enterprise Value. This allows UCB to have a decade-plus visibility on top- and bottom-line growth, in our view. We believe UCB offers growth at a reasonable valuation, the company now trading...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Aaron Brodjanac ... (+7)
  • Aaron Brodjanac
  • Baptiste Salaville
  • Chaima Ferrandon
  • Charlotte Vaisse
  • Marc Lavaud
  • Sven Edelfelt
  • Thomas Zlowodzki
Aaron Brodjanac ... (+7)
  • Aaron Brodjanac
  • Baptiste Salaville
  • Chaima Ferrandon
  • Charlotte Vaisse
  • Marc Lavaud
  • Sven Edelfelt
  • Thomas Zlowodzki
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: Dividend and outlook better than expected. Ackermans & van Haaren: Anticipating an all-time-high result from core segments. Ageas: FY24 in line, strong capital, outlook for upsteams. AMG: Strong 4Q24 beat and 2025F guidance upgrade. CFE: Solid results and balance sheet, outlook weak. CMB.TECH: Cautious on outlook. Corbion: Not so sweet. CTP: Good results, 2025 outlook realistic. D'Ieteren: Boyd's Five-Year Goals. Exor: Ferrari €3bn ABB and €1bn SBB. Sofina: Further ...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Morning Notes : AALB NA, AGS BB, ARGX BB, CFEB BB, CRBN NA, CMBT BB, M...

: AALB NA, AGS BB, ARGX BB, CFEB BB, CRBN NA, CMBT BB, MDXH BB, PNL NA, UCB BB, VAN BB, WDP BB, CTPNV NA, SYENS BB

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch